Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma
NCT02884453Phase 2Unknown
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Jul 2016
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in gastroesophageal junction carcinoma (GEJ), sponsored by Royal Marsden NHS Foundation Trust. Status: unknown.
02
Drugs
ibrutinib
03
Conditions
gastroesophageal junction carcinoma (GEJ)
Beyond the preview
Go deeper on NCT02884453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02884453.